Long-term Efficacy and Safety of Romiplostim in Refractory Aplastic Anemia: Follow-up of a Phase 2/3 Study
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Elderly Patients With Aplastic Anemia: Treatment Patterns and Outcomes in the Real World.
Fattizzo B, Gurnari C, Giammarco S, Ricchiuti A, Awada H, Bortolotti M Am J Hematol. 2025; 100(4):584-591.
PMID: 39878088 PMC: 11886494. DOI: 10.1002/ajh.27611.
Modified Delphi panel consensus recommendations for management of severe aplastic anemia.
Babushok D, DeZern A, de Castro C, Rogers Z, Beenhouwer D, Broder M Blood Adv. 2024; 8(15):3946-3960.
PMID: 38669341 PMC: 11331724. DOI: 10.1182/bloodadvances.2023011642.
References
1.
Frampton J, Lyseng-Williamson K
. Romiplostim. Drugs. 2009; 69(3):307-17.
DOI: 10.2165/00003495-200969030-00006.
View
2.
Winkler T, Fan X, Cooper J, Desmond R, Young D, Townsley D
. Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag. Blood. 2019; 133(24):2575-2585.
PMC: 6566590.
DOI: 10.1182/blood.2019000478.
View
3.
Lee J, Lee S, Jung C, Park S, Keta H, Park S
. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial. Lancet Haematol. 2019; 6(11):e562-e572.
DOI: 10.1016/S2352-3026(19)30153-X.
View
4.
Jang J, Tomiyama Y, Miyazaki K, Nagafuji K, Usuki K, Uoshima N
. Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study. Br J Haematol. 2020; 192(1):190-199.
PMC: 7821109.
DOI: 10.1111/bjh.17190.
View